Literature DB >> 18208824

Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay.

R Dinser1, M Fousse, U Sester, K Albrecht, M Singh, H Köhler, U Müller-Ladner, M Sester.   

Abstract

OBJECTIVE: To compare the efficacy of the conventional skin test and a novel flow cytometric whole blood assay in the diagnosis of latent tuberculosis infection (LTBI) in patients with rheumatological diseases evaluated for treatment with TNF-alpha-blocking agents.
METHODS: Prospective study of 97 consecutively enrolled patients, who were assessed for the presence of LTBI through clinical history, Mendel-Mantoux skin testing and chest X-ray. In addition, T-cell reactivity towards tuberculin (PPD, purified protein derivative) and the Mycobacterium tuberculosis-specific proteins ESAT-6 and CFP-10 was determined ex vivo using a flow cytometric whole blood assay.
RESULTS: After standard screening, 15% of patients receiving TNF-alpha-blocking therapy were pretreated with isoniazide (INH), another 5% of patients did not receive TNF-alpha-blocking therapy because of LTBI. PPD-reactivity in the skin was observed in 14% of patients compared with 39% with the whole blood test. Analysis of the M. tuberculosis-specific response to ESAT-6 and CFP-10 revealed positive results in 16% of patients. Using a decision tree incorporating history, chest X-ray and either skin-test or ESAT-6/CFP-10 results, 18 or 22% of the patients, respectively, were classified as latently infected with M. tuberculosis. Four patients treated with INH because of a positive skin reaction did not show reactivity to ESAT-6/CFP-10 in the whole blood assays. Another six patients not pretreated with INH because of negative skin tests would have received INH, had the results of the whole blood assay been taken into account.
CONCLUSION: The Mendel-Mantoux skin test has a low sensitivity and specificity for the diagnosis of LTBI in this cohort of patients, potentially resulting in both over- and under-treatment with prophylactic INH when compared with the flow cytometric analysis of whole blood T-cell reactivity to proteins specific to M. tuberculosis. Use of T-cell based in vitro tests may help to refine diagnostic testing for LTBI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208824     DOI: 10.1093/rheumatology/kem351

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

1.  ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Authors:  Stefania Girlanda; Paola Mantegani; Elena Baldissera; Patrizia Aiello; Manuela Ratti; Maria Grazia Sabbadini; Claudio Fortis
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

2.  Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis.

Authors:  Cláudia Diniz Lopes Marques; Ângela Luzia Branco Pinto Duarte; Virginia Maria Barros de Lorena; Joelma Rodrigues Souza; Wayner Vieira Souza; Yara de Miranda Gomes; Eduardo Maia Freese de Carvalho
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

3.  Tuberculosis in transplantation: diagnosis, prevention, and treatment.

Authors:  Sarah Kirsch; Martina Sester
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

4.  Performance of QuantiFERON®-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs.

Authors:  Francesca Gabriele; Maria Trachana; Maria Simitsopoulou; Polixeni Pratsidou-Gertsi; Elias Iosifidis; Zoi Dorothea Pana; Emmanuel Roilides
Journal:  World J Pediatr       Date:  2017-06-22       Impact factor: 2.764

5.  Preventing tuberculosis in children receiving anti-TNF treatment.

Authors:  Nuray Aktay Ayaz; Erkan Demirkaya; Yelda Bilginer; Uğur Ozçelik; Nazan Cobanoğlu; Nural Kiper; Nesrin Besbas; Aysin Bakkaloğlu; Seza Ozen
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

Review 6.  Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Frank Hoentjen; Ad A van Bodegraven
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

7.  Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states.

Authors:  Urban Sester; Mathias Fousse; Jan Dirks; Ulrich Mack; Antje Prasse; Mahavir Singh; Ajit Lalvani; Martina Sester
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

8.  Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis.

Authors:  Julia Elsäßer; Martin W Janssen; Frank Becker; Henrik Suttmann; Kai Schmitt; Urban Sester; Michael Stöckle; Martina Sester
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 9.  Immune response to mycobacterial infection: lessons from flow cytometry.

Authors:  Nikoletta Rovina; Marios Panagiotou; Konstantinos Pontikis; Magdalini Kyriakopoulou; Nikolaos G Koulouris; Antonia Koutsoukou
Journal:  Clin Dev Immunol       Date:  2013-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.